Business
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined Fiscal Year 2025, ended March 31, 2025. This past year has been nothing short of transformative, marked by significant clinical progress, strategic expansion, and growing recognition for our pioneering approach to Alzheimer's disease.","length":572,"tagName":"p"},{"type":"text","content":"The Company has filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 ("FYE 2025"), with the U.S. Securities and Exchange Commission (SEC). The report provides a comprehensive overview of the Company's financial performance, operations, and strategic outlook. Investors and other stakeholders can access the full filing on the SEC's website at www.sec.gov or through the Investor Relations section of IGC Pharma's website at www.investor.igcpharma.com.","length":498,"tagName":"p"},{"type":"text","content":""Fiscal Year 2025 stands as a testament to IGC Pharma's unwavering commitment to addressing one of the most pressing global health challenges: Alzheimer's disease," said Ram Mukunda CEO of IGC Pharma. "We have not only advanced our lead asset, IGC-AD1, through critical clinical milestones but have also strategically expanded our reach and solidified our innovative position through AI integration and a growing pipeline. Our progress reflects the dedication of our team, the strength of our scientific foundation, and our relentless pursuit of meaningful solutions for patients and their families. IGC Pharma is not just developing therapies; we are building a future where Alzheimer's is no longer an insurmountable challenge."","length":762,"tagName":"p"},{"type":"text","content":"Highlights of a Pivotal Year for IGC Pharma:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positive Interim Data Reinforces IGC-AD1's Potential:","length":57,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":57,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"April 2, 2024 - IGC Pharma re...